Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pharma Mar stock price, quote, forecast and news

PHM.MC
ES0169501022
A2P9YT

Price

40.76
Today +/-
-0.60
Today %
-1.46 %
P

Pharma Mar stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Pharma Mar stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pharma Mar stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pharma Mar stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pharma Mar's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pharma Mar Stock Price History

DatePharma Mar Price
9/6/202440.76 undefined
9/5/202441.36 undefined
9/4/202441.20 undefined
9/3/202440.64 undefined
9/2/202441.64 undefined
8/30/202440.80 undefined
8/29/202440.58 undefined
8/28/202440.20 undefined
8/27/202440.82 undefined
8/26/202440.88 undefined
8/23/202439.62 undefined
8/22/202439.14 undefined
8/21/202439.24 undefined
8/20/202438.40 undefined
8/19/202437.84 undefined
8/16/202436.78 undefined
8/15/202436.56 undefined
8/14/202435.68 undefined
8/13/202435.78 undefined
8/12/202435.74 undefined

Pharma Mar Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pharma Mar, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pharma Mar from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pharma Mar’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pharma Mar. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pharma Mar’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pharma Mar’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pharma Mar’s growth potential.

Pharma Mar Revenue, EBIT and net profit per share

DatePharma Mar RevenuePharma Mar EBITPharma Mar Net Income
2028e465.2 M undefined308.01 M undefined223.25 M undefined
2027e228.81 M undefined99.98 M undefined131.82 M undefined
2026e171.84 M undefined54 M undefined43.75 M undefined
2025e171.54 M undefined44.94 M undefined35.6 M undefined
2024e159.6 M undefined1.84 M undefined5.2 M undefined
2023158.15 M undefined-4.1 M undefined1.14 M undefined
2022196.34 M undefined44.44 M undefined49.36 M undefined
2021229.83 M undefined92.35 M undefined92.86 M undefined
2020269.96 M undefined156.21 M undefined137.26 M undefined
201985.82 M undefined-17.48 M undefined-11.38 M undefined
2018108.77 M undefined-16.03 M undefined-5.54 M undefined
2017158.88 M undefined-19.54 M undefined-26.75 M undefined
2016180.95 M undefined-18.71 M undefined-24.08 M undefined
2015193.82 M undefined11.3 M undefined6.59 M undefined
2014174.8 M undefined20.24 M undefined13.12 M undefined
2013141.82 M undefined18.96 M undefined11.32 M undefined
2012161.78 M undefined14.57 M undefined6.59 M undefined
2011177.2 M undefined23.85 M undefined4.74 M undefined
2010161.24 M undefined-9.52 M undefined-7.35 M undefined
2009143.63 M undefined-21.2 M undefined-25.88 M undefined
2008122.85 M undefined-37.06 M undefined-40.65 M undefined
200799.87 M undefined-45.33 M undefined-45.08 M undefined
200687.36 M undefined-48.01 M undefined-43.82 M undefined
200582.39 M undefined-39.3 M undefined-37.75 M undefined
200494.66 M undefined-21.85 M undefined-20.67 M undefined

Pharma Mar Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
3233363948568469769482879912214316117716114117419318015810885269229196158159171171228465
-3.139.098.3323.0816.6750.00-17.8610.1423.68-12.776.1013.7923.2317.2112.599.94-9.04-12.4223.4010.92-6.74-12.22-31.65-21.30216.47-14.87-14.41-19.390.637.55-33.33103.95
71.8869.7066.6769.2372.9291.07100.00117.39117.1162.7764.6360.9261.6268.8569.9372.0577.4077.6476.6077.0176.6875.5677.8595.3794.1295.1793.0192.8693.67-----
23232427355184818959535361841001161371251081341481361231038025621318214800000
131354-40-23-21-39-48-45-37-21-92314182011-18-19-16-171569244-41445399308
3.139.092.787.6910.427.14-4.76--30.26-22.34-47.56-55.17-45.45-30.33-14.69-5.5912.998.7012.7711.495.70-10.00-12.03-14.81-20.0057.9940.1722.45-2.530.6325.7330.9943.4266.24
1113912942-20-37-43-45-40-25-74611136-24-26-5-111379249153543131223
---200.00200.0033.33-25.00-55.56-50.00-1,100.0085.0016.224.65-11.11-37.50-72.00-157.1450.0083.3318.18-53.85-500.008.33-80.77120.00-1,345.45-32.85-46.74-97.96400.00600.0022.86204.6570.23
----------------------------------
----------------------------------
14.2414.2414.2414.2411.312.5817.3217.417.417.1817.3117.7217.9718.2218.2518.3518.4818.3618.4218.3918.4418.3818.4418.4418.518.3318.0918.0617.9200000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Pharma Mar Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pharma Mar is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                         
11.778.9610.6912.8512.52164.8890.16143.39131.25119.8138.77100.4797.8662.3463.366.5849.3334.4328.8435.5145.6332.3731.7626.8820.9195.52201.88182.42162.56
12.7114.2611.2111.9918.9621.6331.4433.2235.5421.416.8920.2124.0927.433.0841.4149.5241.1537.8336.2239.5161.8630.5223.0311.1623.6650.5628.9727.2
0000000002.041.832.081.191.611.31.422.634.626.224.642.112.384.573.537.6813.5528.3530.0620.63
2.713.053.53.534.786.146.566.859.2810.619.5210.7819.3326.4424.0429.225.3123.522.2324.422.9922.1623.920.628.911.9310.5427.7539.29
0.070.230.040.040.130.470.780.620.263.893.424.477.17.144.684.82.752.730.771.151.92.232.431.061.3413.915.982.92
27.2526.4925.4328.436.38193.12128.95184.09176.32157.73170.42138.01149.57124.92126.39143.41129.53106.4395.9101.92112.13120.9993.1875.1149.98245.65295.23275.18252.6
26.7726.222.8721.4522.625.6840.3756.4755.9145.2742.641.4639.3339.939.0636.5733.8629.7927.9629.2230.6231.1431.2126.6425.825.530.6134.7247.61
13.4714.9214.041011.2947.6730.58.578.3213.113.059.6110.548.418.418.358.188.87.838.017.227.267.16.961.8721.8311.5750.246.91
0000000000000000000000-2.14000000
22.125.6828.1134.4847.7367.2889.53132.69181.8611.0811.0410.8210.9211.7712.5314.4517.3219.7422.5926.2926.8324.922.3516.666.073.863.232.591.94
0.190.680.653.018.259.417.866.785.23002.552.552.552.552.552.552.552.552.552.552.552.552.5500000
1.591.060.741.241.311.619.386.543.7219.8621.921.9519.4219.9822.3825.526.3732.5132.5526.2532.5834.333.4829.7740.9833.4227.7530.5331.47
64.1168.5566.4270.1791.18161.64177.64211.05255.0289.3188.5986.3982.7682.6284.9387.4288.2893.493.4892.3199.8100.1494.5482.5774.7384.6173.16118.0887.92
91.3795.0491.8598.57127.56354.76306.59395.13431.34247.04259.01224.41232.33207.54211.31230.82217.82199.83189.37194.23211.94221.14187.72157.68124.71330.26368.39393.26340.52
                                                         
10.889.799.799.499.127.999.9910.0410.0410.0410.5710.7911.1111.1111.1111.1111.1111.1111.1111.1111.1111.1111.1311.1311.1311.0111.0111.0111.01
0.550.55015.2714.6221.89184.69225.82224.38223.78282.68283.98324.38323.29323.29323.29323.29323.29323.29323.2969.1969.1971.2871.2871.2871.2871.2871.2871.28
28.5730.4333.3537.9345.7586.2970.2879.2681.89-99.78-137.53-169.8-215.02-257.84-281.27-289.45-287.97-285.73-275.14-261.77-0.49-24.71-51.09-58.81-69.5541.87121.29156.51142.22
000000-0.010000000000000000000000
0000000002933-840-3150113681113121514191915
39.9940.7743.1462.6969.47316.17264.94315.11316.31134.06155.76124.88120.4776.5253.1344.9546.4348.6659.2672.6379.8255.6131.3423.6212.87124.18203.6238.82224.53
5.525.114.447.616.3918.3629.5422.3717.6921.4518.5322.7329.4930.1831.522823.7824.4328.7131.9639.1837.4434.5119.3321.0426.9327.4929.17
6857891929293501300000000000000000000
3.54.213.362.614.445.865.554.556.6811.5112.889.9711.111.958.958.948.688.848.319.4510.0420.0819.289.399.7757.145.3955.151.91
00000000000000000000000000000
11.9312.128.676.236.53.964.5221.0334.7251.5145.6540.7221.6323.8932.7862.8652.6954.7341.3344.4728.6327.9126.428.4831.3316.7814.0314.7314.81
21.0221.516.4312.9318.6326.2128.4555.4663.7880.7179.9769.2255.4565.3271.91103.3289.3787.3674.0682.6370.6287.1683.1172.3860.4494.9286.3597.3295.89
20.6222.4719.2310.7719.069.929.9317.0836.0738.4742.474372.5386.8491.785.3483.0662.0252.944764.9767.5873.6164.9254.7839.8835.327.928.86
0000000003.753.994.074.55.065.466.157.848.559.030000000000
1.261.211.532.032.252.072.557.4815.1910.93.850.941.040.971.111.153.053.193.914.533.3117.98.022.92.0392.7468.8245.0922.33
21.8823.6820.7612.821.311212.4824.5651.2653.1250.3148.0178.0692.8798.2792.6493.9573.7565.8851.5368.2885.4881.6367.8256.81132.62104.1272.9851.19
42.9145.1837.1925.7339.9438.2140.9380.02115.04133.83130.28117.23133.51158.2170.18195.96183.31161.1139.94134.16138.9172.64164.74140.2117.25227.54190.47170.3147.08
82.985.9580.3388.42109.4354.38305.87395.13431.34267.89286.04242.12253.98234.72223.31240.91229.74209.77199.19206.79218.72228.25196.07163.82130.12351.71394.07409.12371.61
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pharma Mar provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pharma Mar's financial health and stability.

Assets

Pharma Mar's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pharma Mar must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pharma Mar after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pharma Mar's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-23-21-39-48-46-42-26-141-113145-24-22-7-231459543-3
1855555555545677667555
000000000000000000000
-16511-6-7-1-3-12-932-4-728-10-16115-72-27-16
-51-9-10-60320-2-1-37666-5710-2151
400001000006655423322
00000020000000-3-7097-2-16
-71-21-33-56-49-35-22-21-46162211-8-1-16-262782538-13
-18-3-2-4-3-8-5-3-3-2-2-10-9-6-4-2-3-3-7-8-15
21-17-5952-1927-6-35010-22-281352232-1191810-43
39-14-5757-1536-108212-12-1919102435-1162619-27
000000000000000000000
183-1-4101613171-13-171013-9-12-31-9-8-1
00542540-794000-260001-33-77-19
151852205092828-11-18-23-5815-7-11-73-27-13-32
-114000055-13-5-5-4201300000
-20000000000000000-8-10-11-11
-34-20-4017-17103-10-124-5-869-1-5781736-89
-89.96-24.78-35.28-60.76-53.02-44.23-28.31-24.99-7.344.2914.2512.611.88-14.51-6.12-18.72-30.05275.9417.8729.47-29.4
000000000000000000000

Pharma Mar stock margins

The Pharma Mar margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharma Mar. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharma Mar.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pharma Mar's sales revenue. A higher gross margin percentage indicates that the Pharma Mar retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pharma Mar's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pharma Mar's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pharma Mar's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pharma Mar. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pharma Mar's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pharma Mar Margin History

Pharma Mar Gross marginPharma Mar Profit marginPharma Mar EBIT marginPharma Mar Profit margin
2028e93.92 %66.21 %47.99 %
2027e93.92 %43.69 %57.61 %
2026e93.92 %31.42 %25.46 %
2025e93.92 %26.2 %20.75 %
2024e93.92 %1.15 %3.26 %
202393.92 %-2.59 %0.72 %
202293.05 %22.63 %25.14 %
202192.85 %40.18 %40.4 %
202094.92 %57.86 %50.85 %
201993.91 %-20.36 %-13.26 %
201895.47 %-14.74 %-5.09 %
201778.01 %-12.3 %-16.83 %
201675.7 %-10.34 %-13.31 %
201576.42 %5.83 %3.4 %
201476.68 %11.58 %7.5 %
201376.37 %13.37 %7.98 %
201277.51 %9 %4.08 %
201177.42 %13.46 %2.68 %
201072.5 %-5.9 %-4.56 %
200969.95 %-14.76 %-18.02 %
200868.64 %-30.16 %-33.09 %
200761.73 %-45.39 %-45.14 %
200661.76 %-54.96 %-50.16 %
200565.37 %-47.71 %-45.82 %
200463.29 %-23.08 %-21.83 %

Pharma Mar Stock Sales Revenue, EBIT, Earnings per Share

The Pharma Mar earnings per share therefore indicates how much revenue Pharma Mar has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pharma Mar earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharma Mar's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharma Mar’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharma Mar's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharma Mar Revenue, EBIT and net profit per share

DatePharma Mar Sales per SharePharma Mar EBIT per sharePharma Mar Earnings per Share
2028e26.08 undefined0 undefined12.51 undefined
2027e12.83 undefined0 undefined7.39 undefined
2026e9.63 undefined0 undefined2.45 undefined
2025e9.62 undefined0 undefined2 undefined
2024e8.95 undefined0 undefined0.29 undefined
20238.83 undefined-0.23 undefined0.06 undefined
202210.87 undefined2.46 undefined2.73 undefined
202112.71 undefined5.11 undefined5.13 undefined
202014.73 undefined8.52 undefined7.49 undefined
20194.64 undefined-0.94 undefined-0.62 undefined
20185.9 undefined-0.87 undefined-0.3 undefined
20178.62 undefined-1.06 undefined-1.45 undefined
20169.84 undefined-1.02 undefined-1.31 undefined
201510.51 undefined0.61 undefined0.36 undefined
20149.51 undefined1.1 undefined0.71 undefined
20137.7 undefined1.03 undefined0.61 undefined
20128.81 undefined0.79 undefined0.36 undefined
20119.59 undefined1.29 undefined0.26 undefined
20108.79 undefined-0.52 undefined-0.4 undefined
20097.87 undefined-1.16 undefined-1.42 undefined
20086.74 undefined-2.03 undefined-2.23 undefined
20075.56 undefined-2.52 undefined-2.51 undefined
20064.93 undefined-2.71 undefined-2.47 undefined
20054.76 undefined-2.27 undefined-2.18 undefined
20045.51 undefined-1.27 undefined-1.2 undefined

Pharma Mar business model

Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases. Pharma Mar is one of the most popular companies on Eulerpool.com.

Pharma Mar SWOT Analysis

Strengths

Pharma Mar SA possess several strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong and diverse portfolio of innovative and effective products.
  • Advanced research and development capabilities.
  • Strong brand reputation and market presence.
  • Solid financial performance and stable revenue growth.
  • Effective strategic partnerships with key stakeholders.

Despite its strengths, Pharma Mar SA also faces certain weaknesses that may hinder its growth and competitiveness. These weaknesses include:

  • Reliance on a few core products for a significant portion of its revenue.
  • Limited geographic presence and market diversification.
  • Potential vulnerability to changes in regulatory environment.
  • Dependency on external suppliers for key ingredients.
  • High research and development costs, which may impact profitability.

There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:

  • Increasing demand for innovative cancer treatments globally.
  • Expansion into new geographic markets to capture untapped potential.
  • Growing trend towards personalized medicine and targeted therapies.
  • Potential partnerships and collaborations with research institutions and pharmaceutical companies.
  • Advancements in technology that could enhance drug development process.

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Weaknesses

Despite its strengths, Pharma Mar SA also faces certain weaknesses that may hinder its growth and competitiveness. These weaknesses include:

  • Reliance on a few core products for a significant portion of its revenue.
  • Limited geographic presence and market diversification.
  • Potential vulnerability to changes in regulatory environment.
  • Dependency on external suppliers for key ingredients.
  • High research and development costs, which may impact profitability.

There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:

  • Increasing demand for innovative cancer treatments globally.
  • Expansion into new geographic markets to capture untapped potential.
  • Growing trend towards personalized medicine and targeted therapies.
  • Potential partnerships and collaborations with research institutions and pharmaceutical companies.
  • Advancements in technology that could enhance drug development process.

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Opportunities

There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:

  • Increasing demand for innovative cancer treatments globally.
  • Expansion into new geographic markets to capture untapped potential.
  • Growing trend towards personalized medicine and targeted therapies.
  • Potential partnerships and collaborations with research institutions and pharmaceutical companies.
  • Advancements in technology that could enhance drug development process.

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Threats

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Pharma Mar Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pharma Mar historical P/E ratio, EBIT, and P/S ratio.

Pharma Mar shares outstanding

The number of shares was Pharma Mar in 2023 — This indicates how many shares 17.916 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pharma Mar earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharma Mar's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharma Mar’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharma Mar's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharma Mar Stock splits

In Pharma Mar's history, there have been no stock splits.

Pharma Mar dividend history and estimates

In 2023, Pharma Mar paid a dividend amounting to 0.65 EUR. Dividend means that Pharma Mar distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Pharma Mar provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Pharma Mar’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Pharma Mar's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Pharma Mar Dividend History

DatePharma Mar Dividend
2028e0.77 undefined
2027e0.77 undefined
2026e0.77 undefined
2025e0.77 undefined
2024e0.77 undefined
20230.65 undefined
20220.65 undefined
20210.6 undefined
20200.48 undefined
20080.06 undefined
20070.06 undefined
20040.12 undefined

Pharma Mar dividend payout ratio

In 2023, Pharma Mar had a payout ratio of 13.97%. The payout ratio indicates the percentage of the company's profits that Pharma Mar distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Pharma Mar represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Pharma Mar could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Pharma Mar's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Pharma Mar Payout Ratio History

DatePharma Mar Payout ratio
2028e17.07 %
2027e16.92 %
2026e16.18 %
2025e18.09 %
2024e16.49 %
202313.97 %
202223.81 %
202111.7 %
20206.41 %
201913.97 %
201813.97 %
201713.97 %
201613.97 %
201513.97 %
201413.97 %
201313.97 %
201213.97 %
201113.97 %
201013.97 %
200913.97 %
2008-2.69 %
2007-2.39 %
200613.97 %
200513.97 %
2004-9.8 %
Unfortunately, there are currently no price targets and forecasts available for Pharma Mar.

Pharma Mar latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2018-0.36 0.12  (133 %)2018 Q2
1

Eulerpool ESG Scorecard© for the Pharma Mar stock

Eulerpool World ESG Rating (EESG©)

85/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
1,157
Scope 2 - Indirect emissions from purchased energy
1,371
Scope 3 - Indirect emissions within the value chain
5,765
Total CO₂ emissions
2,528
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees61
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pharma Mar list of shareholders

%
Name
Stocks
Change
Date
6.24553 % Fernandez Sousa Faro (Jose Maria)1,114,14708/10/2023
5.35038 % Andrade Detrell (Montserrat)954,46008/10/2023
5.20040 % Ortega Mera (Sandra)927,70508/10/2023
5.14588 % Fernandez Puentes (Pedro Francisco)917,97908/10/2023
2.06385 % The Vanguard Group, Inc.368,173-19,5073/31/2024
1.16611 % BlackRock Institutional Trust Company, N.A.208,0231703/31/2024
1.12969 % Norges Bank Investment Management (NBIM)201,527-59,56412/31/2023
1.10099 % Redwheel196,40608/10/2023
0.48550 % Dimensional Fund Advisors, L.P.86,60903/31/2024
0.38541 % BlackRock Advisors (UK) Limited68,754-1,5933/31/2024
1
2
3
4
5
...
10

Pharma Mar Executives and Management Board

Mr. Jose Maria Fernandez Sousa-Faro
Pharma Mar Chief Executive Officer, Executive Chairman of the Board
Compensation 2.75 M
Mr. Pedro Francisco Fernandez Puentes
Pharma Mar Executive Vice Chairman of the Board
Compensation 554,000
Ms. Maria Blanca Hernandez Rodriguez
Pharma Mar Independent Director
Compensation 157,000
Ms. Montserrat Andrade Detrell
Pharma Mar Proprietary Director
Compensation 143,000
Mr. Carlos Solchaga Catalan
Pharma Mar Other External Director
Compensation 142,000
1
2
3
4
...
5

Most common questions regarding Pharma Mar

What values and corporate philosophy does Pharma Mar represent?

Pharma Mar SA represents a set of core values and corporate philosophy that drive its operations. The company focuses on developing innovative therapies in the field of oncology and the treatment of other serious diseases. With a commitment to scientific excellence, Pharma Mar SA aims to create impactful solutions that improve patients' lives. Through strategic collaborations and continuous research, the company strives to deliver cutting-edge pharmaceutical products. Pharma Mar SA's dedication to ethical practices, transparency, and sustainability further reinforces its commitment to stakeholders and the global healthcare community.

In which countries and regions is Pharma Mar primarily present?

Pharma Mar SA is primarily present in several countries and regions. The company has a strong presence in Spain, where it is based and operates its headquarters. Additionally, Pharma Mar SA has expanded its operations to various international markets, including the United States, Germany, Italy, France, and Switzerland. With a global presence, Pharma Mar SA strives to bring its innovative pharmaceutical products and treatments to patients worldwide.

What significant milestones has the company Pharma Mar achieved?

Pharma Mar SA, a leading pharmaceutical company, has achieved significant milestones in its remarkable journey. The company's innovative approach and dedication to drug discovery have yielded remarkable results. Pharma Mar SA's milestones include successful clinical trials for their flagship drugs, receiving regulatory approvals, and securing strategic partnerships with renowned pharmaceutical companies. Furthermore, the company's consistent commitment to scientific research and development has resulted in groundbreaking discoveries that have revolutionized the treatment of various diseases. Through their remarkable achievements, Pharma Mar SA has solidified its position as a pioneering force in the pharmaceutical industry and continues to make invaluable contributions towards improving global healthcare.

What is the history and background of the company Pharma Mar?

Pharma Mar SA is a leading biopharmaceutical company with a rich history and background. Established in 1986, the company is headquartered in Madrid, Spain. Pharma Mar SA focuses on the research, development, and commercialization of innovative marine-derived drugs to address various oncology and rare diseases. With a strong commitment to scientific excellence, Pharma Mar SA has built a diverse pipeline of potential therapies, leveraging the unique properties of marine organisms. The company has garnered global recognition for its breakthrough discovery of marine-derived compounds, including the development of Aplidin® (plitidepsin), a promising anticancer agent undergoing clinical trials. Pharma Mar SA continues to push boundaries in the pharmaceutical industry, striving to improve patients' lives worldwide.

Who are the main competitors of Pharma Mar in the market?

The main competitors of Pharma Mar SA in the market include other pharmaceutical companies operating in the same field and targeting similar market segments. Some notable competitors of Pharma Mar SA may include (examples only, not an exhaustive list): AstraZeneca, Novartis, Roche Holding, Pfizer, and Johnson & Johnson. These companies also focus on researching, developing, and marketing pharmaceutical products, including therapies and treatment options.

In which industries is Pharma Mar primarily active?

Pharma Mar SA is primarily active in the pharmaceutical industry.

What is the business model of Pharma Mar?

The business model of Pharma Mar SA revolves around the research, development, and commercialization of innovative marine-derived pharmaceutical products. Pharma Mar specializes in the development of therapies derived from marine resources, particularly marine microorganisms. By harnessing the therapeutic potential of the sea, the company aims to bring effective treatments to patients suffering from various diseases, including cancer. With a focus on oncology, Pharma Mar seeks to address unmet medical needs and improve patients' lives globally. Through strategic partnerships, clinical trials, and ongoing research, Pharma Mar continues to drive advancements in the field of marine-derived pharmaceuticals.

What is the P/E ratio of Pharma Mar 2024?

The Pharma Mar P/E ratio is 140.45.

What is the P/S ratio of Pharma Mar 2024?

The Pharma Mar P/S ratio is 4.58.

What is the AlleAktien quality score of Pharma Mar?

The AlleAktien quality score for Pharma Mar is 1/10.

What is the revenue of Pharma Mar 2024?

The expected Pharma Mar revenue is 159.6 M EUR.

How high is the profit of Pharma Mar 2024?

The expected Pharma Mar profit is 5.2 M EUR.

What is the business model of Pharma Mar

Pharma-Mar SA is a Spanish pharmaceutical company specializing in the development and marketing of cancer therapies. The company was founded in 1986 and is based in Colmenar Viejo, near Madrid. The company consists of two different business areas: Oncology and Consumer Healthcare. The Oncology division focuses on the development and marketing of innovative cancer drugs based on marine compounds, while the Consumer Healthcare division distributes over-the-counter drugs and cosmetic products. The company's business model is based on a strong research and development department that specializes in the exploration and development of cancer drugs based on marine compounds. They also collaborate with other pharmaceutical companies and research institutions to advance the research and development of cancer drugs. The company has a strong presence in international markets and has distribution partnerships in Europe, America, and Asia, allowing them to market their products worldwide and increase their revenue. Overall, Pharma-Mar SA is dedicated to the research, development, and distribution of cancer drugs, as well as over-the-counter drugs and cosmetic products.

What is the Pharma Mar dividend?

Pharma Mar pays a dividend of 0.65 EUR distributed over payouts per year.

How often does Pharma Mar pay dividends?

The dividend cannot currently be calculated for Pharma Mar or the company does not pay out a dividend.

What is the Pharma Mar ISIN?

The ISIN of Pharma Mar is ES0169501022.

What is the Pharma Mar WKN?

The WKN of Pharma Mar is A2P9YT.

What is the Pharma Mar ticker?

The ticker of Pharma Mar is PHM.MC.

How much dividend does Pharma Mar pay?

Over the past 12 months, Pharma Mar paid a dividend of 0.65 EUR . This corresponds to a dividend yield of about 1.59 %. For the coming 12 months, Pharma Mar is expected to pay a dividend of 0.77 EUR.

What is the dividend yield of Pharma Mar?

The current dividend yield of Pharma Mar is 1.59 %.

When does Pharma Mar pay dividends?

Pharma Mar pays a quarterly dividend. This is distributed in the months of May, August, July, July.

How secure is the dividend of Pharma Mar?

Pharma Mar paid dividends every year for the past 9 years.

What is the dividend of Pharma Mar?

For the upcoming 12 months, dividends amounting to 0.77 EUR are expected. This corresponds to a dividend yield of 1.88 %.

In which sector is Pharma Mar located?

Pharma Mar is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharma Mar kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharma Mar from 6/14/2024 amounting to 0.65 EUR, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.

When did Pharma Mar pay the last dividend?

The last dividend was paid out on 6/14/2024.

What was the dividend of Pharma Mar in the year 2023?

In the year 2023, Pharma Mar distributed 0.65 EUR as dividends.

In which currency does Pharma Mar pay out the dividend?

The dividends of Pharma Mar are distributed in EUR.

All fundamentals about Pharma Mar

Our stock analysis for Pharma Mar Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.